Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn

#1

Press: Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn
Paper: The association between omega-3 supplementation and cognitive decline in older adults 2026

Results
Omega-3 supplementation was associated with significantly accelerated cognitive decline, as evidenced by a faster decrease in MMSE scores (β = -0.266, p < 0.001) and a faster increase in both ADAS-Cog13 (β = 0.823, p < 0.001) and CDR-SB scores (β = 0.205, p < 0.001). This association was not mediated by Aβ deposition, tau pathology, or gray matter atrophy. Instead, longitudinal FDG hypometabolism within AD-vulnerable regions served as a significant mediating pathway, accounting for 30.8%, 40.8%, and 19.0% of the total effect on the decline in MMSE, ADAS-Cog13, and CDR-SB, respectively.
Conclusions
Omega-3 supplementation may be associated with accelerated cognitive decline in older adults, potentially through adverse effects on cerebral synaptic function rather than classical AD proteinopathies. These findings challenge the prevailing view of omega-3 as uniformly beneficial and highlight the need for a cautious reassessment of its widespread use for cognitive protection.

ChatGPT:

  • Journal: serious / legitimate (Impact Factor 7.8 and CiteScore 10.0).
  • Research team: real AD-neurology group with relevant publication footprint, but not a world-leading household-name omega-3 trial group.
  • Paper: credible enough to take seriously, but the result should still be treated as an observational signal, not as causal proof.

Main takeaway: interesting signal, but I would not treat it as proof that omega-3 causes cognitive decline.
Reasons:

  1. Confounding by indication is a big concern.
    People who choose omega-3 supplements may already be more worried about memory, have subtle symptoms, have vascular/metabolic issues, or be following advice after health deterioration. The authors say they found “no pre-existing differences in cognitive or FDG-SUVR trajectories before initiation,” but that does not fully eliminate residual confounding.
  2. ADNI is not a general-population cohort.
    ADNI is enriched for people at risk of Alzheimer’s disease, with detailed imaging and cognitive follow-up. Results may not generalize to healthy 40–70-year-olds taking modest fish oil.
  3. “Omega-3 supplementation” is probably heterogeneous.
    Observational datasets often lack precise information on EPA/DHA dose, brand, oxidation quality, duration, adherence, baseline omega-3 index, fish intake, indication, and co-supplements. Those matter a lot.
  4. The result conflicts with much of the broader prior expectation, but not cleanly with RCT evidence.
    Prior randomized evidence has generally been weak/neutral rather than strongly positive. Cochrane found no cognitive benefit for omega-3 in dementia over six months, and a Nutrition Reviews meta-analysis in non-demented adults found no effect on global cognition but a mild memory benefit.
  5. Dietary omega-3 and supplements should be separated.
    Observational studies of dietary fish/omega-3 often look more favorable than supplement trials. A 2023 review found dietary intake and biomarkers were associated with lower dementia/cognitive-decline risk, while supplement RCT evidence remains much less convincing.
7 Likes
Predicting Alzheimers & Dementia (and minimizing risk)
#2

On the potential risks of omega-3 supplementation, see also:

4 Likes
#3

These results are quite surprising, especially considering the recent ITP results. I’m starting to worry that my supplement stack might be doing more harm than good.

#4

Which recent ITP results? Fish oil had an insignificant and in some cases negative effect on mice in the ITP: Omega 3 makes me depressed: why? - #32 by matthost

2 Likes
#5

What is your personal opinion regarding EPA? Is it still worth it to keep it on my stack despite reta and pitava? You are pretty much the Omega 3 expert :face_with_monocle:

#6

Based on the evidence I found, DHA supplementation seems detrimental.

For EPA-only supplementation, the strongest evidence we have is REDUCE-IT 4g/day: 25% risk reduction https://jamanetwork.com/journals/jama/fullarticle/2773120 (btw, the STRENGTH trial added DHA to EPA and found no benefits. So DHA might have erased EPA’s benefits.)

JELIS 1.8 g/day found a 19% risk reduction, consistent with REDUCE-IT.

EVAPORATE with 4 g/day found coronary plaque stabilization/regression: Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial - PubMed

For depression, we also have some positive signals in meta-reviews.

So I guess, if you already have apoB, blood pressure, and glucose under control, then adding up to 4 g/day EPA-only (Vazkepa/Vascepa) can be good? I don’t take it because the evidence isn’t super strong (some people criticize REDUCE-IT for the placebo chosen, also those were very stick population, what is it like in healthy young people?) and I prefer to limit my stack.

3 Likes
#7

Another point: REDUCE-IT looked at Tg 135–499 mg/dL; LDL 41–100 mg/dL and EVAPORATE Tg 135–499 mg/dL; LDL >40 to ≤115 mg/dL.

Are EPA’s benefits replicable to people with normal Tg?

JELIS was total cholesterol ≥250 mg/dL. But it was open-label (not double blind), without placebo, with low-intensity statins, in Japanese people (high-fish-intake population).

Conclusion: if you have Tg > 135 mg/dL, 4 g/day Vazkepa makes sense. If Tg < 135 mg/dL and low apoB: unclear…

#8

Funding bias can affect nutrition science. Research funded by the food industry has consistently yielded results that favor the sponsor, undermining the credibility of the field.

AI response to a query on the (condensed) history of omega-3 supplementation:

“The story of omega-3s is a textbook example of how industry marketing, consumer hope, and evolving science can intersect, creating a narrative that’s often more compelling than the data.”

“The modern push for omega-3 supplements began in earnest around 2000, driven by early research that linked them to heart health”

"However, a significant challenge arose in mid-2013 when a major study linked omega-3s to an increased risk of prostate cancer. This led to a $149 million drop in retail sales, forcing the industry to take direct action. GOED launched a targeted marketing campaign in Charlotte, North Carolina, that included TV commercials, digital ads, billboards, retail signage, and even placing dietitians on local news to promote omega-3 benefits " (Global Organization for EPA and DHA (GOED))

“A constant stream of positive messaging is necessary to counter negative news and maintain consumer demand”

Where Omega-3s Likely Provide Real Benefit

  • Cardiovascular Health: Omega-3 supplementation appears to reduce triglycerides (a type of fat in the blood), with one analysis showing a significant 14.7% reduction. It also modestly lowers total cholesterol. For high-risk individuals, one study found a reduction in 5-year coronary heart disease risk from 3.2% to 2.5%. The protective effect may be stronger for the EPA component alone than for combined EPA/DHA supplements. “Recent meta-analysis and intervention studies suggest that omega-3 FAs improve macrovascular health outcomes in humans”.
  • Cognitive Function (General Adults): A major 2025 meta-analysis of 58 randomized controlled trials found that supplementation may lead to a “modest improvement” in certain cognitive functions like attention, perceptual speed, and language in adults.
  • Specific Medical Conditions: Promising, but preliminary, evidence exists for specific patient groups. For example, omega-3s “may have beneficial effects in organ transplant recipients, particularly in reducing total cholesterol, diastolic blood pressure, and 3-month rejection rate”, and they are being studied for conditions like rheumatoid arthritis.

:x: Where Evidence Shows Little to No Benefit (or Potential Harm)

  • Alzheimer’s Disease & Late-Life Cognitive Decline: This is the most significant area of caution. Numerous rigorous trials on elderly individuals show that omega-3s do not slow cognitive decline or improve memory loss in those with mild to moderate Alzheimer’s disease. A 2025 study specifically warned they “may increase the risk of cognitive decline” in elderly individuals who carry the APOE ε4 gene, a major risk factor for Alzheimer’s. The effect was a faster decrease in scores on tests for memory, attention, and language. This strongly suggests that blanket advice to take them for brain health in old age is not supported by science.
  • Cardiovascular Events in the General Population: While they improve blood markers, the clinical impact is less certain. A key 2025 analysis concluded that “the evidence for omega-3 supplementation remains mixed” for preventing major cardiovascular events in healthy people. Their effect on key metrics like arterial plaque volume is negligible.

This is a good paper (IMO) with lots of forest plots that can help you make a decision.

Omega-3 supplementation seems a little iffy to me and is not on my supplement list.

#9

This paper certainly raises concern but isn’t definitive by any means. The OP is openly anti fish oil supplementation which is fine and I respect that, but it also leads to an incentive to post trials showing negative outcomes from fish oil. A simple google shows a 2023 paper from the same Alzheimer’s disease network database reporting a dose dependent decrease in Alzheimer’s disease/dementia from fish oil supplementation. Other studies show improvements in brain FDG metabolism with higher omega3 status. I’m on the bike so haven’t had time to critically evaluate the papers but if you have 2 papers from the same database showing opposite findings you have to wonder if the statistical massage or some other unmeasured variable wasn’t at play. I don’t think omega3’s are miracle supplements but there’s a big difference between no benefit vs overt harm. With a plethora of data showing mild benefit or at least no harm, you need more than a single retrospective paper to change the paradigm.

1 Like
#10

Yes, there was some evidence initially, but then clinical trials found nothing or harm (VITAL-DEP found that fish oil supplementation causes depression, for instance). Most papers showing benefits are association studies, and they often don’t adjust for income (rich people eat more fish and take better care of their health) or for healthy-user bias (healthy people supplement more, with anything).

I’m not “anti fish oil supplementation” as a religious belief. I did supplement with fish oil after skimming through the evidence and believing some of the “longevity influencers”. Then I dug deeper and found out that the evidence wasn’t there, so I stopped supplementing. I’m very sad that fish oil supplementation doesn’t have proven benefits.

Anyway, in the end, we all make our own decisions for our own health. I just want people to know the pros and cons so they can make the best-informed choice.

If you want a literature review, click on the 3 links here: Omega-3 Supplements May Increase Risk of Cognitive Decline, Scientists Warn - #2 by adssx

3 Likes
#11

Why not just stick to fish a couple of times a week - of course careful with choices (wild caught salmon, sardines, baby calamari etc.). The literature doesn’t show much risk with fish consumption (if you consume low pollution species) and it can slightly boost your omega-3 index.

If focused on CVD and trigs, pure EPA is an option. I in fact do supplement with pure EPA 500mg three times a week, but it’s for other reasons (anti-inflammatory etc.), but do admit to completely unscientific irrational fear of high doses, so I cannot see myself taking the 1-4g doses for CVD. We’re not completely rational (I am not!), and fish oil supplementation is one area with people having strong intuitions/biases. I’m superstitiously sticking with fish and very low EPA topping off. YMMV.

1 Like
#12

I approve this message!

1 Like
#13

An evaluation of this paper:

Novelty

This is the first longitudinal human study to demonstrate a statistically significant acceleration of cognitive decline associated with omega-3 use over a long-term (5-year) window. It uniquely identifies FDG-PET hypometabolism as the mediator, providing a potential biological explanation for why many Randomized Controlled Trials (RCTs) have failed to show benefit. [Confidence: Medium]

Critical Limitations

  • Exposure Misclassification: The study relied on retrospective self-reporting of “fish oil” use and lacked precise dosage or adherence data.

  • Oxidation Variability: Commercial fish oil oxidation levels were not measured; the observed harm might be specific to oxidized “shelf” supplements rather than fresh or stabilized oils.

  • Healthy User Bias Paradox: The findings contradict the typical “healthy user bias” where supplement users usually show better outcomes due to overall lifestyle, suggesting the effect size must be significant to overcome this bias.

  • Missing Data: There was no stratification by omega-3 subtype (DHA vs. EPA) or baseline plasma omega-3 levels, which are critical for determining the “therapeutic window”.

The Oxidative Trap: Why Your Fish Oil Might Be Accelerating Cognitive Decline

For decades, omega-3 polyunsaturated fatty acids have been the “golden child” of neuroprotection, touted as essential for maintaining cognitive health in aging brains. However, a provocative longitudinal study published in 2026 suggests that for many older adults, the fish oil habit may be doing more harm than good. Leveraging data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), researchers found that omega-3 supplementation was not just ineffective, but was significantly associated with a faster rate of cognitive deterioration.

The study tracked participants over a median of five years, using a battery of cognitive tests including the MMSE and ADAS-Cog13. The results were stark: users of omega-3 supplements exhibited a significantly accelerated decline in global cognition compared to matched non-users. Intriguingly, this cognitive “crash” did not correlate with the traditional hallmarks of Alzheimer’s disease. Supplementation had no impact on the accumulation of amyloid-beta plaques or tau tangles, nor did it affect the rate of gray matter atrophy.

Instead, the culprit appears to be “synaptic starvation”. Using FDG-PET imaging, the researchers discovered that omega-3 users suffered from progressive hypometabolism—a decline in the brain’s ability to utilize glucose—within regions most vulnerable to Alzheimer’s. This metabolic failure mediated up to 40.8% of the accelerated cognitive decline observed in the study.

The authors suggest a “Double-Edged Sword” hypothesis. While omega-3s are anti-inflammatory, their highly unsaturated structure makes them exceptionally prone to lipid peroxidation within mitochondria. In the context of the aging brain, which already faces an elevated oxidative burden, high-dose or oxidized fish oil supplements may trigger a “self-reinforcing vicious cycle” of mitochondrial damage and energy failure. This research calls for an immediate and cautious reassessment of the widespread use of fish oil for cognitive longevity, particularly when using commercial formulations prone to oxidation.

Actionable Insights

The primary takeaway from this research is that “more is not better” when it comes to omega-3 supplementation for brain health. If you are supplementing for longevity, you must prioritize the oxidative stability of your source. Commercial fish oils often have high oxidation levels, which may flip the molecule from a neuroprotector to a pro-oxidant. Consider switching to whole-food sources or high-stability formulations like krill oil or algae-based DHA that are stored under rigorous conditions.

Furthermore, baseline testing is non-negotiable. Data suggests that individuals with already high levels of omega-3 or low baseline inflammation derive the least benefit and may face the highest risk of “over-saturation” and subsequent oxidative stress. Before continuing a high-dose regimen, assess your Red Blood Cell (RBC) Omega-3 Index. Finally, monitor your brain’s metabolic health. Since the harm observed was mediated by glucose hypometabolism, interventions that support mitochondrial efficiency—such as metabolic flexibility and exercise—may be necessary to counteract potential supplement-induced oxidative burdens.

Context

  • Institution: Third Military Medical University, Chongqing Medical University.
  • Country: China.
  • Journal Name: The Journal of Prevention of Alzheimer’s Disease (JPAD).
  • Impact Evaluation: The impact score of this journal is 6.4 (CiteScore 2026), evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal (High within its specific niche of Alzheimer’s prevention).
2 Likes
#14

Wow, didn’t see this coming. (But those follow more closely, probably have. @desertshores What is your stack? As a 61 yr old in semi-retirement, I don’t have the extra resources to maintain current products, especially when studies (like shown here) prove they are minimally effective and could be detrimental. In my head, I always imagined fish oil cleaning out the arteries, the capsules are so clean and convenient.

#15

Thanks for sharing. The issue of fish oil supplementation is indeed quite complex, and it may take synthesizing a large body of research to reach a conclusion.

#16

It’s also important not to talk about “fish oil” but about DHA and EPA (and maybe ALA and DPA). I think this is why the debate and the research on “omega 3” are blurry: people (and researchers) mix up fish consumption, fish oil, EPA-only, DHA-only, EPA-dominant oils, and DHA-dominant oils. Those are different compounds.

#17

That’s another reason why you might want to get more carotenoids into the brain (lutein, zeaxanthin, mesozeaxanthin, lycopene, astaxanthin).

Neuroprotective and Neurotrophic Effects of Astaxanthin on the Brain

1 Like
#18

Yeah, thanks for catching that mistake. I realized I’ve unconsciously slipped into the habit of using ‘fish oil’ as a blanket term for ‘omega-3,’ even though plenty of people take krill oil, cod liver oil, and various others. I probably picked it up from the pharmacy PhDs I follow who do the exact same thing.

When it comes to omega-3 supplements, I’ve seen pharmacy grads and PhDs cite 50 to 60 papers (covering both the pros and cons) just to write a basic educational article for the public, and they still struggle to explain it clearly. I actually spent a massive amount of time back in the day trying to figure out the perfect routine for optimal results. Long story short, omega-3 is a highly complex supplement, and if you dig too deep, it’s really easy to fall down a rabbit hole.